ArticleDiscover oncology2025
Single cell transcriptomic analysis reveals molecular mechanisms of chemoresistance and immune microenvironment remodeling in ovarian cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundChemotherapy resistance remains a major clinical challenge in ovarian cancer treatment, limiting therapeutic efficacy and patient survival. Understanding the molecular mechanisms underlying chemoresistance at the single-cell level is crucial for developing targeted therapeutic strategies.
methodsWe performed comprehensive single-cell RNA sequencing analysis on primary and chemoresistant ovarian cancer samples to characterize cellular heterogeneity and identify resistance-associated molecular signatures. Cell type identification, differential gene expression analysis, functional enrichment analysis, and immune microenvironment characterization were conducted to elucidate chemoresistance mechanisms. Computational predictions were validated by RT-qPCR analysis of four key resistance genes (BIRC5, ABCB1A, ABCG2, BCL2) in SKOV3 and SKOV3-CDDP cell lines.
resultsOur analysis identified nine distinct cell populations within the ovarian cancer microenvironment, revealing extensive transcriptional reprogramming in chemoresistant tumors. Key chemoresistance genes including Abcb1a, Abcg2, Bcl2, Birc5, Nek2, Inhba, Irs1, and Prc1 showed differential expression patterns across cell types. Epithelial cells and proliferating cells exhibited elevated expression of multiple resistance markers, particularly Birc5. Functional analysis revealed enrichment of ribosome biogenesis, protein synthesis machinery, and amoeboid-type cell migration pathways in resistant cells. Macrophage polarization states were significantly altered, and immune checkpoint molecules showed coordinated upregulation, indicating comprehensive immune microenvironment reprogramming. RT-PCR validation confirmed single-cell predictions with significant upregulation in resistant cells: BIRC5 (4.2-fold, p < 0.001), ABCB1A (3.8-fold, p < 0.001), ABCG2 (2.9-fold, p < 0.01), and BCL2 (2.1-fold, p < 0.05).
conclusionsThis study provides a comprehensive single-cell atlas of chemoresistance in ovarian cancer, revealing cell type-specific resistance mechanisms and immune evasion strategies. The identified molecular signatures offer potential therapeutic targets for overcoming chemotherapy resistance and improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.